Literature DB >> 27353063

Chronic Chagas cardiopathy in Chile. Importance of Trypanosoma cruzi burden and clinical evaluation.

Werner Apt1, Arturo Arribada2, Inés Zulantay3, Miguel Saavedra3, Catalina Muñoz3, Bruno Toro3, Bastián Vega3, Jorge Rodríguez4.   

Abstract

Currently there are no biological markers to indicate which individuals with chronic indeterminate period of Chagas disease develop heart disease and who will remain all his life in this phase. The aim of this survey was to determine if Trypanosoma cruzi burden is related to the presence of heart disease in patients with chronic Chagas disease. 200 patients who had not been treated, 100 with cardiopathy and 100 without, groups A and B respectively, were submitted to clinical study and electrocardiogram, Echo-Doppler was performed for group A in which all important known causes of cardiopathy were discarded. In both groups xenodiagnosis, conventional PCR and quantitative PCR were undertaken. The 100 cardiopaths had 133 electrocardiographic alterations most of them in grade II of the New York Heart Association classification. 98 cardiopaths were classified in grade I by Echo-Doppler and only 2 cases were in grade III due to low ejection fraction. The difference in average parasitemia in patients of group A and B was not significant and no statistically differences were observed between average parasitemia of cardiopaths grade II versus grade I of NYHA. This results allow to characterize same clinical, electrocardiographical and parasitological features in chagasic cardiopaths of Chile.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiomyopathy; Chronic chagas disease; PCR; Parasite burden; Trypanosoma cruzi

Mesh:

Year:  2016        PMID: 27353063     DOI: 10.1016/j.actatropica.2016.06.025

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  5 in total

1.  Monitoring the parasite load in chronic Chagas disease patients: comparison between blood culture and quantitative real time PCR.

Authors:  Daniella Alchaar D'Ávila; Lúcia Maria C Galvão; Giovane R Sousa; Constança Britto; Otacilio C Moreira; Egler Chiari
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

2.  IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in Bolivia.

Authors:  Clara Vásquez Velásquez; Graciela Russomando; Emilio E Espínola; Zunilda Sanchez; Kota Mochizuki; Yelin Roca; Jimmy Revollo; Angelica Guzman; Benjamín Quiroga; Susana Rios Morgan; Roberto Vargas Ortiz; Alberto Zambrana Ortega; Eida Espinoza; Juan Eiki Nishizawa; Mohamed Gomaa Kamel; Mihoko Kikuchi; Shusaku Mizukami; Kesara Na-Bangchang; Nguyen Tien Huy; Kenji Hirayama
Journal:  PLoS Negl Trop Dis       Date:  2019-09-25

3.  Association Between Trypanosoma cruzi DNA in Peripheral Blood and Chronic Chagasic Cardiomyopathy: A Systematic Review.

Authors:  Pau Bosch-Nicolau; Juan Espinosa-Pereiro; Fernando Salvador; Adrián Sánchez-Montalvá; Israel Molina
Journal:  Front Cardiovasc Med       Date:  2022-01-31

4.  Over-dispersed Trypanosoma cruzi parasite load in sylvatic and domestic mammals and humans from northeastern Argentina.

Authors:  Gustavo Fabián Enriquez; Jacqueline Bua; María Marcela Orozco; Natalia Paula Macchiaverna; Julián Antonio Alvarado Otegui; Hernán Darío Argibay; María Del Pilar Fernández; Ricardo Esteban Gürtler; Marta Victoria Cardinal
Journal:  Parasit Vectors       Date:  2022-01-24       Impact factor: 3.876

5.  A Specific IL6 Polymorphic Genotype Modulates the Risk of Trypanosoma cruzi Parasitemia While IL18, IL17A, and IL1B Variant Profiles and HIV Infection Protect Against Cardiomyopathy in Chagas Disease.

Authors:  Alexandra Gomes Dos Santos; Elieser Hitoshi Watanabe; Daiane Tomomi Ferreira; Jamille Oliveira; Érika Shimoda Nakanishi; Claudia Silva Oliveira; Edimar Bocchi; Cristina Terra Gallafrio Novaes; Fatima Cruz; Noemia Barbosa Carvalho; Paula Keiko Sato; Edite Hatsumi Yamashiro-Kanashiro; Alessandra Pontillo; Vera Lucia Teixeira de Freitas; Luiz Fernando Onuchic; Maria Aparecida Shikanai-Yasuda
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.